Management strategies and clinical outcomes of venous thromboembolism in patients with antiphospholipid syndrome in the direct oral anticoagulant era: Insight from the COMMAND VTE Registry-2
Takahiro Kuno a), Norimichi Koitabashi a), Yugo Yamashita c), Takeshi Morimoto d), Yoshiaki Ohyama a) b), Noriaki Takama a), Masaru Obokata a), Ryuki Chatani e), Kazuhisa Kaneda c), Yuji Nishimoto f), Nobutaka Ikeda g), Yohei Kobayashi h), Satoshi Ikeda i), Kitae Kim j), Moriaki Inoko k), Toru Takase l), Shuhei Tsuji m), Maki Oi n),
Takuma Takada o), Kazunori Otsui p), Jiro Sakamoto q), Yoshito Ogihara r), Takeshi Inoue s), Shunsuke Usami t), Po-Min Chen u), Kiyonori Togi v), Seiichi Hiramori w), Kosuke Doi x), Hiroshi Mabuchi y), Yoshiaki Tsuyuki z), Koichiro Murata aa), Kensuke Takabayashi ab), Hisato Nakai ac), Daisuke Sueta ad), Wataru Shioyama ae), Tomohiro Dohke af), Ryusuke Nishikawa c), Hideki Ishii a), Takeshi Kimura ab), On behalf of the COMMAND VTE Registry-2 Investigators
a) Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
b) Clinical Investigation and Research Unit, Gunma University Hospital, Maebashi, Japan
c) Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
d) Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan
e) Department of Cardiovascular Medicine, Kurashiki Central Hospital, Kurashiki, Japan
f) Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan
g) Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan
h) Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
i) Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
j) Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
k) Cardiovascular Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan
l) Department of Cardiology, Kinki University Hospital, Osaka, Japan
m) Department of Cardiology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan
n) Department of Cardiology, Japanese Red Cross Otsu Hospital, Otsu, Japan
o) Department of Cardiology, Tokyo Women’s Medical University, Tokyo, Japan
p) Department of General Internal Medicine, Kobe University Hospital, Kobe, Japan
q) Department of Cardiology, Tenri Hospital, Tenri, Japan
r) Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu, Japan
s) Department of Cardiology, Shiga General Hospital, Moriyama, Japan
t) Department of Cardiology, Kansai Electric Power Hospital, Osaka, Japan
u) Department of Cardiology, Osaka Saiseikai Noe Hospital, Osaka, Japan
v) Division of Cardiology, Nara Hospital, Kinki University Faculty of Medicine, Ikoma, Japan
w) Department of Cardiology, Kokura Memorial Hospital, Kokura, Japan
x) Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan
y) Department of Cardiology, Koto Memorial Hospital, Higashiomi, Japan
z) Division of Cardiology, Shimada General Medical Center, Shimada, Japan
aa) Department of Cardiology, Shizuoka City Shizuoka Hospital, Shizuoka, Japan
ab) Department of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan
ac) Department of Cardiovascular Medicine, Sugita Genpaku Memorial Obama Municipal Hospital, Obama, Japan
ad) Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
ae) Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan
af) Division of Cardiology, Kohka Public Hospital, Koka, Japan
Highlights
• The guideline recommendations for DOAC use are weaker for VTE with APS.
• In the COMMAND VTE Registry-2, most patients with APS-associated VTE were anticoagulated with DOACs.
• The prognosis of VTE with APS was rather better than that of VTE without APS.
• Retrospective design and lack of APS risk stratification limit generalizability.
• Further studies with APS risk profiling are needed to validate these findings.